Reduction by propranolol of urinary hydroxyproline excretion in human hyperthyroidism: a beta-receptor blockade effect or a membrane stabilizing mechanism?
In order to investigate the mechanism whereby oral propranolol administration reduces the increased rate of urinary hydroxyproline excretion (UHxE) of patients with hyperthyroidism, a comparison was made of the effects of the oral administration of propranolol-timolol, propylthiouracil (PTU), and a placebo to patients with hyperthyroidism and to normal controls. Propranolol decreased the pulse rate (P less than 0.01), serum triiodothyronine (T3) level (P less than 0.05), and UHxE (P less than 0.01) without modifying the serum free thyroxine index (FT4I) or parathormone (PTH) level. Timolol decreased the pulse rate (P less than 0.01) to the same extent as propranolol, had no effect on T3, FT4I, or PTH, and failed to decrease UHxE. Administration of PTU decreased the T3 level (P less than 0.05) to a similar extent as propranolol without modifying the FT4I or PTH level and had no effect on UHxE. Placebo administration had no effect. These results suggest that the reduction of UHxE by propranolol is not due to the beta-receptor-blocking properties of propranolol nor mediated by the propranolol-induced decrease in the level of T3 but is probably due to the membrane-stabilizing properties of propranolol.
D000328:Adult; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D006980:Hyperthyroidism / Q000188:drug therapy / Q000652:urine*; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use*; D011441:Propylthiouracil / Q000627:therapeutic use; D013974:Thyroxine / Q000097:blood; D013999:Timolol / Q000627:therapeutic use; D014284:Triiodothyronine / Q000097:blood
D014284:Triiodothyronine; D011441:Propylthiouracil; D013999:Timolol; D011433:Propranolol; D013974:Thyroxine; D006909:Hydroxyproline